Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients
Active pharmaceutical ingredients (APIs) can exist in different polymorphic forms as well as in amorphous state. Polymorphic and amorphous forms of APIs can differ in physicochemical properties which in turn can significantly influence their therapeutic safety and effectiveness of the treatment. This review focuses on benefits and limitations of polymorphic and amorphous forms of APIs used in preformulation and formulation studies. Authors present their work on safety precautions for the use of polymorphic and amorphous forms of APIs, analytical techniques used for their identification as well as methods of their preparation especially in regard to limitations of labile APIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 22(2016), 32 vom: 09., Seite 4975-4980 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talaczynska, Alicja [VerfasserIn] |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 04.12.2017 Date Revised 28.07.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM263156362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM263156362 | ||
| 003 | DE-627 | ||
| 005 | 20231224203259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0877.xml |
| 035 | |a (DE-627)NLM263156362 | ||
| 035 | |a (NLM)27494530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talaczynska, Alicja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2017 | ||
| 500 | |a Date Revised 28.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Active pharmaceutical ingredients (APIs) can exist in different polymorphic forms as well as in amorphous state. Polymorphic and amorphous forms of APIs can differ in physicochemical properties which in turn can significantly influence their therapeutic safety and effectiveness of the treatment. This review focuses on benefits and limitations of polymorphic and amorphous forms of APIs used in preformulation and formulation studies. Authors present their work on safety precautions for the use of polymorphic and amorphous forms of APIs, analytical techniques used for their identification as well as methods of their preparation especially in regard to limitations of labile APIs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Dzitko, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Cielecka-Piontek, Judyta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 22(2016), 32 vom: 09., Seite 4975-4980 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:32 |g day:09 |g pages:4975-4980 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2016 |e 32 |b 09 |h 4975-4980 | ||